Enliven Therapeutics (ELVN)CHIEF SCIENTIFIC OFFICER sold ~$30K

~$30K

Approx. value · 1,500 sh @ $20.03

932K

Holds after · shares reported

Traded

Sep 23, 2025

Filed

Sep 25, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 28, 2025Insider · 1 personInsiders: 2 sales (~$67K)
2. Aug 7, 2025Insider · 1 personInsiders: 2 sales (~$122K)
3. Aug 19, 2025InsiderOfficer sold ~$98K of ELVN shares in the open market
4. Aug 20, 2025InsiderCEO sold ~$30K of ELVN shares in the open market
5. Aug 21, 2025InsiderOfficer sold ~$150K of ELVN shares in the open market
6. Aug 27, 2025InsiderCFO sold ~$67K of ELVN shares in the open market
7. Sep 8, 2025InsiderOfficer sold ~$135K of ELVN shares in the open market
8. Sep 17, 2025InsiderCEO sold ~$95K of ELVN shares in the open market
9. Sep 19, 2025Insider · 2 peopleInsiders: 3 sales (~$156K)
10. Sep 23, 2025 · this disclosureInsiderOfficer sold ~$30K of ELVN shares in the open market

What came next

1. Sep 23, 2025InsiderCEO sold ~$56K of ELVN shares in the open market
2. Sep 26, 2025Insider · 2 peopleInsiders: 2 sales (~$155K)
3. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
4. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
5. Dec 9, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On December 11, 2025, Enliven Therapeutics, Inc. (the “ Company ”) announced the appointment of Richard Fair as the Company’s President and Chief Executive Officer and as a member of the board of directors (the “ Board ”) of the Company, effective as of December 11, 2025 (the “ Effective Date ”).”
6. Jan 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On January 6, 2026, the board of directors (the “ Board ”) of Enliven Therapeutics, Inc. (the “ Company ”) appointed Scott Garland to serve as a Class I director, with a term expiring at the Company’s 2027 annual meeting of stockholders, and as the Chair of the Nominating and Corporate Governance Committee of the Board (the “ Nominating Committee ”), effective January 7, 2026.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Enliven Therapeutics

For Enliven Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 6 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ELVN page.

Other recent filings by Joseph P Lyssikatos, CHIEF SCIENTIFIC OFFICER

• SEC Form 4 at Enliven Therapeutics (ELVN)Sep 30, 2025
• SEC Form 4 at Enliven Therapeutics (ELVN)Sep 23, 2025
• SEC Form 4 at Enliven Therapeutics (ELVN)Sep 23, 2025
• SEC Form 4 at Enliven Therapeutics (ELVN)Aug 21, 2025
• SEC Form 4 at Enliven Therapeutics (ELVN)Aug 21, 2025

The full history of Joseph P Lyssikatos, CHIEF SCIENTIFIC OFFICER is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Enliven Therapeutics

• SEC Form 4Oct 6, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its ELVN page.